Combination of Anti a-Gal-PpIX Conjugate and Photodynamic Therapy for the Diagnosis and Elimination of HeLa and CaSki Cells
Pages 106-112
Fabiola Cabrera-Cedillo, Anabelle Manzo-Sandoval, Yolanda Medina-Flores, María Edith Medina-Escutia, Olga Mata-Ruíz, Alfredo Cruz-Orea, Jorge Adrián Garduño-Medina, Jóse Manuel de la Rosa-Vázquez and Eva Ramón-Gallegos
DOI: http://dx.doi.org/10.6000/1927-7229.2015.04.03.3
Published: 07 September 2015

Abstract: The photodynamic therapy (PDT) is a specific and alternative treatment for premalignant and malignant diseases. The α-Gal epitope is expressed in red blood cells and nucleated cells of placental mammals not primates, but absent in old world monkeys, apes and humans. α-Gal epitope has been found in cervical biopsies HPV positive, in biopsies at different stages of cervical intraepithelial neoplasia and in cell lines such as HeLa and CaSki. The aim of this work was to obtain IgG anti a-Gal monoclonal antibody (mAb) and evaluate its usefulness in the photodynamic therapy in order to diagnosis and eliminate infected cells by HPV, types 16 and 18. From the 4C1F6D5G7B8 hybridoma line was obtained a producer hybridoma of IgG3, the mAb was conjugated with PpIX (IgG-PpIX). The IgG-PpIX conjugated was capable of identify the α-Gal epitope present at the membrane of HeLa and CaSki cell lines by immunocitochemistry. The cell lines were exposed to IgG-PpIX and irradiated with a LED system at 635 nm at an energy dose of 64.3 J/cm². The PDT using IgG anti α-Gal monoclonal antibody has effect on the viability of cervical carcinoma cells; the mortality results obtained were, in descendent order, HeLa (66.9 %) and CaSki (50.8 %). It was possible to conclude that PDT using the immunoconjugate IgG anti α-Gal-PpIX is effective to diagnosis and eliminate cervical carcinoma cells.